Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.
Metrics to compare | SLGL | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipSLGLPeersSector | |
|---|---|---|---|---|
P/E Ratio | −20.2x | 6.3x | −0.5x | |
PEG Ratio | −2.79 | 0.15 | 0.00 | |
Price/Book | 7.0x | 1.6x | 2.6x | |
Price / LTM Sales | 9.5x | 2.3x | 3.3x | |
Upside (Analyst Target) | 68.5% | 21.5% | 44.3% | |
Fair Value Upside | Unlock | 17.1% | 4.9% | Unlock |